Introduction {#s1}
============

Liquid laundry detergent pods (LDPs) are unit dose fabric washing products consisting of about 32--50 mL of concentrated liquid detergent wrapped in a water-soluble membrane. According to the International Association for Soaps, Detergents and Maintenance Products (AISE), these products are intended to improve environmental sustainability of liquid laundry detergent consumption by providing the correct dosage for washing needs and reducing packaging size.[@R1] However, following their launch in the UK, Irish, and French markets in 2001, a few reports of paediatric poisonings and injuries highlighted the potential for these products to cause eye damage,[@R2] pulmonary and central nervous system toxicity[@R5] and serious laryngopharyngeal injuries.[@R6] [@R11] A decade later, these products were introduced into other national markets without considering the need for specific measures to prevent exposures. Consequently, these countries started to document cases of patients with LDP exposures presenting with severe respiratory, oesophageal, gastric,[@R12] eye[@R19] and skin injuries,[@R22] together with cases of altered mental status.[@R12] [@R13] Studies based on large series of cases handled by Poison Control Centres (PCCs) or emergency departments confirmed that LDP-related cases are more likely to develop signs/symptoms and moderate/high severity clinical effects than those exposed to traditional laundry detergents (TLDs).[@R20] [@R25]

LDPs were initially launched in the Italian market in mid-August 2010; they were sold in see-through outer packaging by a major company (MC) and 1 year later in the same way by other companies (OCs). In the days after the MC-LDPs launch, the National Poison Control Centre in Milan (NPCCMi) started receiving an increasing number of requests for toxicological assistance of young children exposed to laundry detergents and with unexpected respiratory and ocular effects. It became immediately evident that the observed events were associated with the new product.[@R22] Therefore, NPCCMi contacted the company manufacturing the product associated with the reported cases, AISE and the Ministry of Health to make the case for taking preventive measures. This alert initiated the monthly monitoring of exposures to laundry detergents by NPCCMi and the Italian National Institute of Health.

After considering the information provided about cases of exposure to LDPs, a series of voluntary initiatives were undertaken by the MC and OCs: in January 2011, the precautionary statement "keep out of reach of children", together with the corresponding icon, was introduced during MC-LDP television advertisements. Furthermore, the icon was made more prominent on the see-through outer packaging. In January 2012, an additional opening/closing latch was added to the lid of the outer packaging of MC-LDPs to make it more difficult for young children to open. Between May and June 2012, the MC and OCs launched an educational campaign in major newspapers and magazines to promote safe use and storage of LDPs. Finally, since August 2012, MC-LDPs have begun to be marketed in opaque outer packaging. Subsequently, the Ministry decree of 18 December 2012,[@R32] made the measures proposed by AISE mandatory.[@R1] From January 2013, the LDPs see-through outer packaging had to be labelled with the precautionary statements "keep away from children" and "close the lid/bag properly" together with the corresponding standard icons or it had to be sold with a pamphlet reporting the same precautionary statement and corresponding icon. From June 2013, the outer packaging of the newly commercialised products needed to be opaque with a closure impeding the ability of young children to open the packaging ---that is, requiring a coordinated action of both hands and more strength to open it, together with a yellow label reporting the above indicated precautionary statements and corresponding icons. Of note, in January 2014, LDPs still available in see-through outer containers had to be withdrawn from the market.

Our study aimed to compare the main characteristics of paediatric exposures to LDPs and TLDs that occurred in Italy between September 2010 and June 2015 and to analyse changes in exposure rates and trends after the introduction of preventive measures during the study period.

Methods {#s2}
=======

Data sources {#s2a}
------------

Each year, NPCCMi receives approximately 42 000 reports of human exposure to different types of agents, accounting for more than 60% of all cases referred to the Italian PCCs. Most requests for toxicological assistance handled by NPCCMi are made by hospitals (60% of cases) and the general public (30% of cases) throughout Italy. Assistance with diagnosis and treatment of poisonings is provided by medical toxicologists, usually over the phone. For each case handled, the consulting toxicologist uses a standard form to collect the following categories of data: demographics, exposure characteristics (eg, substance/commercial product, route of exposure, circumstances, dose and latency between exposure and onset of clinical effects), signs and symptoms, treatment and outcome. Data on the quantity of MC-pods and OCs-pods sold were provided by the MC, expressed as million units sold/month between February 2010 and December 2014.

Case selection criteria {#s2b}
-----------------------

For this study, all cases of unintentional exposure to laundry detergents between 1 September 2010 and 30 June 2015 were extracted from the NPCCMi database. These cases were searched using NPCCMi hierarchical code of products, which qualifies the exposure of interest as non-pharmaceutical (first level), household cleaning product (second level) and laundry detergent (third level).[@R33] The subsequent associated code levels are intended to provide the following pieces of information: type of detergent and physical form (fourth level) ---that is, TLD, liquid/solid; LDP, liquid/half liquid and half solid, product brand name and company (fifth level). Unintentional exposure to laundry detergents was found in 3470 cases, of which 2958 (85%) were in children aged \<5 years and were included in the study. Patients aged ≥5 years were excluded from the study. Among the included cases, 1150 patients were exposed to TLDs (39%) and 1649 were exposed to LDPs (56%). One hundred fifty-nine cases (5%) were excluded from the study because it was unknown if the laundry detergent was a TLD or a LDP. Among patients exposed to LDPs, 1188 (72%) were exposed to MC-LDPs and 461 (28%) to OCs-LDPs.

Variables {#s2c}
---------

The variables analysed included: site of case management (hospital/non-hospital), demographic characteristics (age and gender; month and year of exposure), route of exposure, clinical effects and treatments. The product companies were classified into two groups---MC, covering 100% to 50% of the Italian market during the study period, and OCs. Data collected for each symptomatic case were reviewed by one of the authors (FD), a clinical toxicologist, to evaluate the association between clinical effects and exposure. Additionally, severity of outcome was graded according to the Poisoning Severity Score,[@R34]---that is, *none*---no signs/symptoms; *low*---mild, transient and spontaneously resolving signs/symptoms, including eye irritation/redness, rash, skin redness/irritation, oral cavity irritation/redness, emesis (one to three episodes), diarrhoea (one to three episodes), self-resolving cough, sore tongue/mouth/throat; *moderate*---pronounced or prolonged signs/symptoms, including corneal ulceration, skin erythema/burns, emesis (more than three episodes), diarrhoea (more than three episodes), persistent cough, difficulty in breathing not requiring intubation, burning sensation of the mouth, transient drowsiness/central nervous system depression; *high*---life-threatening signs/symptoms or resulting in significant residual disability or disfigurement, including oedema of epiglottis/glottis/pharynx/larynx, difficulty in breathing requiring intubation, persistent drowsiness/ central nervous system depression, corrosive injuries of the gastrointestinal tract, metabolic acidosis, melena; *fatal*---death as a result of exposure or of direct complications of the exposure effects; *not associated*---no signs/symptoms possibly related to the exposure; *insufficient data*---the available information is indicative of a causal relationship between exposure and an adverse health effect but it is inadequate for severity grading.

Statistical methods and ethical considerations {#s2d}
----------------------------------------------

The characteristics of patients exposed to the two main categories of laundry detergents were compared by Pearson\'s χ^2^ test or Fisher\'s exact test. The following occurrence measures were calculated: mean number of cases of exposure/day by month, year and category of laundry detergent, mean number of cases of exposure to LDPs/million units sold by month, year and company ---that is, MC vs OCs. Information on the quantity sold between September 2010 and December 2015 was provided by the MC. To determine whether an occurrence change had taken place during the study period, the series of rates estimates were analysed according to the procedure described by Taylor for performing a change-point analysis.[@R35] This procedure iteratively uses a combination of cumulative sum charts (CUSUM) and bootstrapping analysis, which provides for each detected point a confidence level indicating how confident the analysis is that the change actually occurred, and a CI indicating how well the time of change point has been pinpointed. Changes at 95% or higher confidence level of rates calculated as number of patients exposed to LDPs/millions units sold by month and company were used to define pre- and post-change periods for subsequent analyses. The mean numbers of cases of exposure to LDPs/month observed in the pre- and post-change periods, adjusted by quantity sold, were compared using analysis of variance. Regression analysis was subsequently used to quantify the exposure period effect according to the change in the mean number of cases/month, along with its 95% CIs.

Further statistical analyses were carried out to check the sensitivity to different distributional assumptions---that is, Poisson regression, using the quantity sold as an offset. To account for variance heterogeneity, regression models were also used on transformed data. In particular, the square root transformation was used to stabilise the variance. Two logistic regression models were used to measure the effect of exposure to laundry detergents as a risk factor for clinical effects (none; at least one) and their severity (none/low severity; moderate/high severity), by maximum likelihood estimate of the ORs and the related 95% CIs, adjusted by age (\<1 year; 1--2 years; 3--4 years) and exposure period (pre-change-point period; post-change-point period).

The analyses were performed using STATA statistic package V.11 and Taylor change-point analyzer (StataCorp, Stata Statistical Software: release 12. College Station, TX: StataCorp LP, 2011; Taylor W Change-Point Analyzer 2.0 shareware program. Libertyville, Illinois: Taylor Enterprises).

This study was approved by the ethical committee of Niguarda Hospital.

Results {#s3}
=======

General characteristics and management site {#s3a}
-------------------------------------------

The main characteristics of patients exposed to TLDs and LDPs are described in [table 1](#INJURYPREV2016042263TB1){ref-type="table"}.

###### 

Characteristics of children aged \<5 years and exposed to laundry detergents in Italy between September 2010 and June 2015

  Characteristics            LDPs   TLDs   Total                 
  -------------------------- ------ ------ ------- ------ ------ ------
  Gender\*\*\*                                                   
   Female                    791    48.0   470     40.9   1261   45.1
   Male                      856    51.9   680     59.1   1536   54.9
   Unknown                   2      0.1    0       0.0    2      0.1
  Age (years)\*\*\*                                              
   \<1                       95     5.8    52      4.5    147    5.3
   1                         621    37.7   489     42.5   1110   39.7
   2                         484    29.4   415     36.1   899    32.1
   3                         289    17.5   135     11.7   424    15.1
   4                         160    9.7    59      5.1    219    7.8
  Route of exposure\*\*\*                                        
   Single route              1452   88.1   1072    93.2   2524   90.2
    Ingestion                1363   82.7   1025    89.1   2388   85.3
    Eye                      76     4.6    28      2.4    104    3.7
    Skin                     13     0.8    19      1.7    32     1.1
   Multiple routes           197    11.9   73      6.3    270    9.6
    Ingestion and eye        84     5.1    17      1.5    101    3.6
    Ingestion eye and skin   27     1.6    8       0.7    35     1.3
    Ingestion and skin       28     1.7    9       0.8    37     1.3
    Eye and skin             54     3.3    36      3.1    90     3.2
    Other                    4      0.2    3       0.3    7      0.3
   Unknown                   0      0.0    5       0.4    5      0.2
  Management site\*\*\*                                          
   Hospital                  1123   68.1   477     41.5   1600   57.2
   Private residence         526    31.9   673     58.5   1199   42.8

\*\*\*p\<0.001.

†The column percentages were calculated using the total number of patients exposed to LDPs (n=1649), TLDs (n=1150) and total (n=2799), respectively.

LDP, laundry detergent pod; TLD, traditional laundry detergent.

The two groups exposed to either TLDs or LDPs showed different distribution by gender age, and route of exposure (p\<0.001, respectively). In comparison with patients exposed to TLDs, patients exposed to LDPs included a higher proportion of female subjects (48% vs 41%), tended to be older, with a higher proportion of children aged 3 years (18% vs 12%) or 4 years (10% vs 5%), and were more often exposed via multiple routes (12% vs 6%), mainly ingestion in combination with eye and/or skin (8% vs 3%). Children exposed to LDPs were more often managed at hospital (68% vs 42%, p\<0.001).

Clinical effects and treatments {#s3b}
-------------------------------

As shown in [table 2](#INJURYPREV2016042263TB2){ref-type="table"}, patients exposed to LDPs more often had clinical effects (75% vs 22%, p\<0.001), and developed moderate/high severity effects (13% vs \<1% (based on one case of moderate severity), p\<0.0001). No deaths associated with laundry detergent exposure were seen. Among symptomatic cases, those exposed to LDPs more often developed gastrointestinal (76% vs 66%, p\<0.01) oropharyngeal (27% vs 12%, p\<0.001) and respiratory (19% vs 11%, p\<0.01) effects than those exposed to TLDs. A number of signs were observed only among patients exposed to LDPs, including lips/oral cavity oedema and de-epithelisation (7 cases, respectively), laryngospasm/bronchospasm (19 cases), lung sounds such as wet rales (14 cases) and stridor (7 cases), bronchial hypersecretion (11 cases), respiratory failure (6 cases), glottis/oesophagus caustic injuries/erosion (5 cases), glottis/epiglottis oedema (3 cases), chemical pneumonia (3 cases), corneal abrasion (22 cases) and rash (8 cases).

###### 

Clinical effects associated with laundry detergents among children aged \<5 years exposed in Italy between September 2010 and June 2015

                                                            LDPs   TLDs   Total                 
  --------------------------------------------------------- ------ ------ ------- ------ ------ ------
  Association between exposure and clinical effects\*\*\*                                       
   None/not associated                                      393    23.8   882     76.7   1275   45.6
   Insufficient data                                        23     1.4    18      1.6    41     1.5
   Associated                                               1233   74.8   250     21.7   1483   53.0
  Severity of clinical effects\*\*\*                                                            
   Low                                                      1076   87.3   249     99.6   1325   89.3
   Moderate                                                 147    11.9   1       0.4    148    10.0
   High                                                     10     0.8    0       0.0    10     0.7
  Main clinical effects                                                                         
   Gastrointestinal\*\*                                     937    76.0   166     66.4   1103   74.4
    Vomiting                                                897    72.7   154     61.6   1051   70.9
    Diarrhoea                                               129    10.5   8       3.2    137    9.2
    Abdominal pain                                          26     2.1    4       1.6    30     2.0
    Nausea                                                  23     1.9    8       3.2    31     2.1
    Heartburn                                               8      0.6    2       0.8    10     0.7
   Oropharyngeal\*\*\*                                      330    26.8   31      12.4   361    24.3
    Hyperaemia oral cavity                                  170    13.8   9       3.6    179    12.1
    Irritation/pharyngeal pain                              140    11.4   14      5.6    154    10.4
    Drooling                                                108    8.8    5       2.0    113    7.6
    Lips hyperaemia                                         7      0.6    4       1.6    11     0.7
    Lips/oral cavity oedema                                 7      0.6    0       0.0    7      0.5
    Lips/oral cavity de-epithelisation                      7      0.6    0       0.0    7      0.5
   Respiratory\*\*                                          228    18.5   28      11.2   256    17.3
    Cough                                                   208    16.9   25      10.0   233    15.7
    Dyspnoea                                                20     1.6    4       1.6    24     1.6
    Laryngospasm/bronchospasm                               19     1.5    0       0.0    19     1.3
    Stridor                                                 7      0.6    0       0.0    7      0.5
    Wet rales                                               14     1.1    0       0.0    14     0.9
    Bronchial hypersecretion                                11     0.9    0       0.0    11     0.7
    Respiratory failure                                     6      0.5    0       0.0    6      0.4
    Glottis/oesophagus caustic injuries/erosion             5      0.4    0       0.0    5      0.3
    Glottis/epiglottis oedema                               3      0.2    0       0.0    3      0.2
    Chemical pneumonia                                      3      0.2    0       0.0    3      0.2
   Ocular                                                   209    17.0   44      17.6   253    17.1
    Hyperaemia                                              198    16.1   39      15.6   237    16.0
    Irritation/pain                                         184    14.9   34      13.6   218    14.7
    Lachrymation                                            35     2.8    3       1.2    38     2.6
    Photophobia                                             24     1.9    2       0.8    26     1.8
    Corneal abrasion                                        22     1.8    0       0.0    22     1.5
    Ptosis                                                  19     1.5    1       0.4    20     1.3
    Dermal                                                  76     6.2    10      4.0    86     5.8
    Hyperaemia                                              36     2.9    4       1.6    40     2.7
    Oedema                                                  20     1.6    1       0.4    21     1.4
    Rash                                                    8      0.6    0       0.0    8      0.5
    Macule                                                  5      0.4    1       0.4    6      0.4

\*\*p\<0.01; \*\*\*p\<0.001.

†The column percentages referring to the 'association between exposure and clinical effects' were calculated using the total number of patients exposed to LDPs (n=1649), TLDs (n=1150) and total (n=2799), respectively; the column percentages referring to 'severity of clinical effects' and the 'main clinical effects' were calculated using the total number of patients with associated clinical effects exposed to LDPs (n=1233), TLDs (n=250) and total (n=1483), respectively. The percentages referring to 'main clinical effects' may not add up to 100% because some patients had more than one clinical effect.

LDP, laundry detergent pod; TLD, traditional laundry detergent.

In both groups the vast majority of patients received at least one treatment (LDPs: 99%; TLDs, 94%), and, more specifically, at least a symptomatic treatment (LDPs: 92%; TLDs: 84%) ([table 3](#INJURYPREV2016042263TB3){ref-type="table"}). Patients exposed to LDPs were more frequently treated with H~2~ blockers (32% vs 6%, p\<0.001), steroids (4% vs 1%, p\<0.001), antibiotics (3% vs 0.3%, p\<0.001) and fluids intravenous (2% vs 0.6%, p\<0.01).

###### 

Treatments reported for children aged \<5 years and exposed to laundry detergents in Italy between September 2010 and June 2015

                                                 LDPs   TLDs   Total                 
  ---------------------------------------------- ------ ------ ------- ------ ------ ------
  At least one treatment\*\*\*                                                       
   No                                            18     1.1    74      6.4    92     3.3
   Yes                                           1631   98.9   1076    93.6   2707   96.7
   Symptomatic treatment\*\*\*                   1522   92.3   962     83.7   2484   88.7
    Antacids/mucosal protection                  1396   84.7   942     81.9   2338   83.5
    H2 blockers\*\*\*                            521    31.6   69      6.0    590    21.1
    Steroids\*\*\*                               66     4.0    13      1.1    79     2.8
    Antibiotics\*\*\*                            49     3.0    4       0.3    53     1.9
    Fluids intravenous\*\*                       37     2.2    7       0.6    44     1.6
    Other\*\*                                    44     2.7    12      1.0    56     2.0
   Antidote                                      1029   62.4   587     51.0   1616   57.7
    Dimethicone/simethicone\*\*\*                1029   62.4   587     51.0   1616   57.7
   Decontamination/absorption prevention\*\*\*   295    17.9   103     9.0    398    14.2
    Dilute/irrigate/wash---ocular\*\*\*          162    9.8    56      4.9    218    7.8
    Emesis/ipecac\*\*\*                          109    6.6    20      1.7    129    4.6
    Dilute/irrigate/wash---dermal                62     3.8    37      3.2    99     3.5
    Activated charcoal                           4      0.2    1       0.1    5      0.2
   Supportive care                               7      0.4    0       0.0    7      0.3
    Artificial ventilation                       6      0.4    0       0.0    6      0.2
    Intubation                                   1      0.1    0       0.0    1      0.0
   Unknown                                       3      0.2    1       0.1    4      0.1

\*\*p \<0.01; \*\*\*p \<0.001.

†The column percentages were calculated using the total number of patients exposed to LDPs (n=1649), TLDs (n=1150) and total (n=2799), respectively. Percentages might not add up to 100% because some patients received more than one treatment.

LDP, laundry detergent pod; TLD, traditional laundry detergent.

In both groups, antidotal therapy referred only to dimethicone/simethicone administration, with a significantly higher percentage of patients treated among those exposed to LDPs (62% vs 51%, p\<0.001).

None of the patients exposed to TLDs was given supportive care, while seven patients exposed to LDPs required support ventilation and one patient was intubated.

Rate changes and trends {#s3c}
-----------------------

The monthly mean number of patients/day exposed to TLDs compared with the two LDPs groups---that is, MC-LDPs and OCs-LDPs, is shown in [figure 1](#INJURYPREV2016042263F1){ref-type="fig"}A, B. A change is indicated by an interruption of the background colour. No change-points were identified for the mean number of patients/day exposed to TLDs (overall estimated average: 0.65 cases/day) ([figure 1](#INJURYPREV2016042263F1){ref-type="fig"}A, B). The mean number of patients/day exposed to MC-LDPs underwent a change in December 2012 (CI December 2012 to December 2012) at a confidence level of 100% ([figure 1](#INJURYPREV2016042263F1){ref-type="fig"}A). Before the observed change the estimated average was 1.03 cases/day, while it became 0.36 cases/day in the post-change period. Three consecutive changes were observed for the mean number of patients/day exposed to OCs-LDPs ([figure 1](#INJURYPREV2016042263F1){ref-type="fig"}B). They included an upward change detected in April 2012 (CI April 2012 to April 2012) at a confidence level of 100%, with estimated averages increasing from 0.24 cases/day (August 2011 to March 2012) to 0.53 cases/day (April to November 2012), and two subsequent rate decreases. The first one, identified in December 2012 (CI December 2012 to June 2013; confidence level: 98%), indicated that between December 2012 and September 2013 the estimated average was reduced from 0.53 to 0.38 cases/day; the second one, identified in October 2013 (CI April 2013 to March 2014; confidence level: 98%), indicated that between October 2013 and June 2015 the observed average was further reduced from 0.38 to 0.25 cases/day.

![Trends of monthly mean number of cases/day exposed to major company (MC)-laundry detergent pods (LDPs) versus traditional laundry detergents (TLDs) (A); other companies (OCs)-LDPs versus TLDs (B) and trends of number of cases/million caps sold exposed to MC-LDPs and OCs-LDPs (C).](injuryprev-2016-042263f01){#INJURYPREV2016042263F1}

The change-point analysis based on the number of patients exposed to LDPs/million units sold by month and company is shown in [figure 1](#INJURYPREV2016042263F1){ref-type="fig"}C. The observed results confirmed an abrupt change of MC-LDP exposure rates in December 2012 (CI October 2012 to December 2012; confidence level: 100%). In the pre-change-point period the estimated average was 1.88 cases/million units sold, while in the post-change-point period (December 2012 to December 2014) it was reduced to 0.86 cases/million units sold. No change was detected for OCs-LDP exposure rates (overall estimated average: 0.95 cases/million units sold).

Analysis of variance performed taking into account the quantity of LDPs sold, confirmed that in the post-change-point period---that is, between December 2012 and December 2014, there was a statistically significant reduction in the mean number of patients exposed to MC-LDPs, accounting for −19.6 cases/month (95% CI −23.2 to −16.1, p\<0.0001). The sensitivity analysis supported the normal based inference (Poisson period coefficient=−0.77, p\<0.001). However, when using the transformed data to take into account the data heterogeneity of variance, the statistical significance of the period effect was reduced (Poisson period coefficient=−0.26, p=0.054).

Risk analyses of clinical effects and their severity {#s3d}
----------------------------------------------------

The logistic regression analysis carried out on all patients exposed to laundry detergents ([table 4](#INJURYPREV2016042263TB4){ref-type="table"}, model 1) showed that the odds of having at least one clinical effect, adjusted by exposure period and age, was similarly increased among patients exposed to MC-LDPs (OR=10.5; 95% CI 8.6 to 12.8) and OCs-LDPs (OR=11.3; 95% CI 8.8 to 14.7) in comparison with TLDs. The analysis focusing only on patients exposed to LDPs ([table 4](#INJURYPREV2016042263TB4){ref-type="table"}, model 2) showed that those exposed to MC-LDPs were more likely (OR=1.8; 95% CI 1.2 to 2.7) to develop moderate/high severity clinical effects in comparison with OCs-LDPs. Furthermore, the odds of having moderate/high severity effects was four times higher for children aged \<1 year than for those aged 3--4 years (reference group) (OR=3.9; 95% CI 2.2 to 7.0).

###### 

Logistic regression models for clinical effects (model 1) and their severity (model 2) after exposure to laundry detergents

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Model 1\                                               Cases\   At least one clinical effect\         Unadjusted OR (95% CI)   Adjusted OR (95% CI)
  Including all patients exposed to laundry detergents   (n)      (%)                                                            
  ------------------------------------------------------ -------- ------------------------------------- ------------------------ ----------------------
  Age (years)                                                                                                                    

   \<1                                                   147      61.9                                  1.2 (0.8 to 1.7)         1.4 (0.9 to 2.2)

   1--2                                                  2009     50.7                                  0.7 (0.6 to 0.9)         1.0 (0.8 to 1.3)

   3--4                                                  643      58.2                                  1.0                      1.0

  Laundry detergent                                                                                                              

   TLDs                                                  1150     21.7                                  1.0                      1.0

   MC-LDPs                                               1188     74.3                                  10.4 (8.6 to 12.6)       10.5 (8.6 to 12.8)

   OCs-LDPs                                              461      75.9                                  11.4 (8.8 to 14.7)       11.3 (8.8 to 14.7)

  Exposure period                                                                                                                

   September 2010--November 2012                         1593     55.7                                  1.0                      1.0

   December 2012--June 2015                              1206     49.3                                  0.8 (0.7 to 0.9)         1.0 (0.9 to 1.3)

  Model 2\                                               Cases\   Moderate/high severity outcomes (%)   Unadjusted OR\           Adjusted OR\
  Including patients exposed to LDPs                     (n)                                            (95% CI)                 (95% CI)

  Age (years)                                                                                                                    

   \<1                                                   95       25.3                                  3.9 (2.2 to 6.9)         3.9 (2.2 to 7.0)

   1--2                                                  1105     8.8                                   1.1 (0.7 to 1.6)         1.1 (0.8 to 1.7)

   3--4                                                  449      8.0                                   1.0                      1.0

  Laundry detergent                                                                                                              

   OCs-LDPs                                              461      6.9                                   1.0                      1.0

   MC-LDPs                                               1188     10.5                                  1.6 (1.1 to 2.4)         1.8 (1.2 to 2.7)

  Exposure period                                                                                                                

   September 2010--November 2012                         1033     8.7                                   1.0                      1.0

   December 2012--June 2015                              616      10.9                                  1.3 (0.9 to 1.8)         1.5 (1.0 to 2.1)
  -----------------------------------------------------------------------------------------------------------------------------------------------------

LDP, laundry detergent pod; MC, major company; OCs, other companies; TLD, traditional laundry detergent.

Discussion {#s4}
==========

The results of this study corroborate findings from previous investigations showing that paediatric exposure to LDPs are more hazardous than those to TLDs.[@R2]

The main characteristics of paediatric patients exposed to LDPs and TLDs in Italy were similar to those reported in a previous study based on data from the US National Poison Data System.[@R30] In particular, both studies show that among patients exposed to LDPs the percentages of those aged 3 and 4 years, exposed via multiple routes, managed at a hospital and with clinical effects are higher than those reported for TLDs.

In both countries children exposed to LDPs have higher odds of experiencing one or more clinical effect than those exposed to TLDs. The OR based on the Italian data (OR=10.8; 95% CI 9.0 to 12.9) was more than twice that reported in the US study (OR=3.9; 95% CI 3.7 to 4.1). This observation might be explained by several factors, including differences in the population served,[@R33] [@R36] pod users' behaviour and products on the market. The Italian study also highlighted a higher odds of having high severity effects for patients exposed to MC-LDPs than for those exposed to OCs-LDPs. This observation deserves particular attention since it might be related to differences in soluble packaging and/or intrinsic toxicity of mixtures.

During the study the number of patients exposed to TLDs was stable (0.65 cases/day), whereas a sharp, statistically significant decrease of exposure to MC-LDPs was seen in December 2012. The estimated values were reduced from 1.03 cases/day and 1.88 cases/million units sold (observed between September 2010 and November 2012) to 0.36 cases/day (observed between December 2012 and June 2015), and 0.86 cases/million units (observed between December 2012 and December 2014). In December 2012 a statistically significant reduction of the number of patients exposed daily to OCs-LDPs was also detected, reducing from 0.53 cases/day (observed between April and November 2012) to 0.38 cases/day (observed between December 2012 and September 2013). A further statistically significant reduction occurred in October 2013, when the estimated daily number of cases was reduced to 0.25 cases/day.

The initial changes seen in December 2012 occurred 4 months after the introduction of opaque outer packaging by the MC for the majority of LDPs marketed in Italy. This action might have been taken by some of the OCs at the same time since a decrease of the number of patients exposed to OCs/day was also detected. Previous preventive measures, including an information campaign for safe use of LDCs, launched between May and June 2012, and improvement of the outer packaging lid to make it more difficult for children to open, started in January 2012, were not followed by any detectable effect on exposure frequency. The second change, specifically with reference exposure to OCs-LDPs, occurred in Italy 5 months after it became compulsory to produce the new products in opaque outer-packaging with a closure impeding the ability of young children to open it.[@R32] The available observations suggest that reducing the visibility of MC-LDPs effectively prevents young children from exposures, whereas other preventive measures seem to be poorly effective if the product is easily visible.

Exposures to LDCs are more frequently associated with moderate/high severity clinical effects than exposure to TLDs, and their attractiveness to children and intrinsic toxicity remains a major concern for prevention of hazardous exposures and injuries.

Like studies based on data from PCCs, our investigation has a number of limitations. First, it relies on cases voluntarily submitted to NPCCMi, representing an unknown proportion of those actually occurring in the served population. Information is mainly collected during the telephone call while the PCC specialist is providing diagnosis and treatment recommendations; this implies that systematic differences may occur in data collection for cases of higher severity owing to the stress of management. Nevertheless, PCCs are the most informative source for poisoning and can raise an alert and guarantee surveillance of specific exposures.

About 5% of cases initially extracted from the NPCCMi database were excluded from the study because the type of laundry detergent patients were exposed to was unknown. Among these cases, 77% were asymptomatic and the remaining 23% reported low severity outcomes. Distributions by age and site of management were similar to those observed for TLDs, suggesting that most of these patients were exposed to this type of detergent.

Two years after the introduction in Italy of obscured outer packaging for LDCs, the same measure was made compulsory in Europe,[@R37] together with other requirements for soluble packaging, including addition of an aversive agent to discourage children from consuming the product, ensuring the pods retained their liquid content for at least 30 s when placed in water at 20°C and resisted a certain degree of standard mechanical compression.

Surveillance of LDP-related cases identified by national PCCs are needed to evaluate the effect of the new measures recently made compulsory in Europe and adopted voluntarily in the USA.[@R30]

###### What is already known on the subject

-   Previous investigations have shown that laundry detergents in pods have the potential to cause corrosive eye damage, pulmonary toxicity and serious laryngopharyngeal injuries in young children.

-   Prevention of hazardous exposures to these products remains a major concern.

###### What this study adds

-   Making these products less visible through the adoption of opaque outer packaging is likely to reduce the occurrence of exposure to pods.

-   Further efforts are needed to reduce attractiveness to children of laundry detergents in pods and reduce their ability to cause injuries and poisoning following exposure.
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